News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Policy
Novartis International AG Painkiller Prexige Gets “Not Approvable” Letter in U.S.
September 27, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
ZURICH, Sept 27 (Reuters) - U.S. regulators have rejected Novartis AG's (NOVN.VX: Quote, Profile, Research) Prexige painkiller, a move that had been expected after Australia withdrew the drug on concerns over liver side-effects.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
Europe
MORE ON THIS TOPIC
Podcast
M&A Ticks Up, ASCO Excites and Vaccines Cause More Drama
June 4, 2025
·
2 min read
·
Heather McKenzie
Tariffs
Rare Disease, Cell and Gene Therapy at Risk From Trump Tariffs, Industry Says
June 3, 2025
·
4 min read
·
Annalee Armstrong
Government
Fake Citations Plague RFK Jr.’s MAHA Report
May 30, 2025
·
2 min read
·
Tristan Manalac
Lung cancer
Merck, Daiichi Sankyo Pull Lung Cancer Filing for ADC, Citing Underwhelming Survival Findings
May 29, 2025
·
2 min read
·
Tristan Manalac